Trials / Completed
CompletedNCT00239330
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
An Open-label, Randomised, Multi-centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 824 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | |
| DRUG | Atorvastatin |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2005-02-01
- Completion
- 2005-02-01
- First posted
- 2005-10-17
- Last updated
- 2010-11-19
Locations
26 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00239330. Inclusion in this directory is not an endorsement.